Andrew A. DeFrancesco, CEO and Director, acquired 450,000 Common Shares on a direct ownership basis at a price of US$0.500 through a private transaction on September 8th, 2020. This represents a $296,798 investment into the company's shares and an account share holdings change of greater than 100%.
SOL Global Investments is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.
SOL Global Investments Corp, formerly Scythian Biosciences Corp, is a Canada-based investment company. The Company is focused on offering strategic investments and partnerships across cultivation, distribution and retail complement the Company's research and development (R&D) program with the University of Miami. It is engaged in the process of developing drug therapies. The Company conducts a project regarding development of a cannabinoid-based combination drug therapy for the treatment of concussions and traumatic brain injury. The Company also provides a research in area of treatment of gastro-inflammatory disease.
No Comments